Per-Patient Costs of Metastatic Prostate Cancer Estimated at $31,427
Increase in annual attributable costs observed over time, from $28,311 in 2007-2013 to $37,055 in 2014-2017
On-Site Genetic Testing for Prostate Cancer Increases Patient Compliance
Implementation of on-site guideline-based genetic testing for prostate cancer patients increased compliance from 33.3 to 98.7 percent
2001 to 2021 Saw Decline in Physician Work Hours
However, trend offset by increase in advanced practice professionals weekly work hours
Trends in Genitourinary Cancers Examined in the United States
Among non-Hispanic Whites, highest incidence rates seen in Northeast for bladder cancer, Appalachia for kidney cancer
FDA Approves Gene Therapy for Tough-to-Treat Bladder Cancer
About 57,000 men and 18,000 women are diagnosed with bladder cancer annually
Direct-to-Consumer Testosterone Not Offered in Accordance With Guidelines
Most direct-to-consumer platforms offer testosterone therapy despite consumer reporting normal testosterone levels, free testosterone
Artificially Sweetened Drinks May Up Risk for Urinary Incontinence
Higher risk seen among women drinking one or more beverages per day
U.S. Deaths Drop in 2022, But Still Higher Than Prepandemic Levels
COVID-19 will remain the third-largest killer for 2022, behind heart disease and cancer, even with the reduced numbers
Air Pollution Tied to Multimorbidity Status, Severity
Higher exposures to particulate matter and nitrogen dioxide associated with multimorbidity status in dose-dependent manner
Preprint, Peer-Reviewed Pairs of Studies Generally Concordant
Sample sizes, primary end points, interpretations mainly concordant for studies published on medRxiv, then in journals
